Cell culture bioreactors
Cell Culture

We work with most cell lines used for manufacturing monoclonal antibodies and recombinant proteins, including CHO, NS/0, BHK, 293 as well as murine hybridomas, and all selection systems used with these lines. We have also worked with several different selection systems such as dhfr / methotrexate CHO, mycophenolic acid/xanthine, and G418 systems. Our experience includes attached or surface dependent as well as suspension culture types.

For more information, click here.

For the latest GBI news
click here




For additional information, please contact us:
954-327-9639
800-814-8600 Ext 139

info@GoodwinBio.com

In Our World-Class Facilities

GBI occupies a facility of over 28,000 sq. ft. that is utilized for GMP manufacturing and process development, QA and QC labs and support services. Manufacturing equipment and its parameters are monitored 24-hour via a computer controlled alarm system. GBI is equipped with emergency backup generators in the event of a power loss. GBI has a facility staff on site to aid in monitoring and maintenance of manufacturing equipment and its associated utilities.



We Welcome Audits

We're proud of our facility and our staff. Stop by and see for yourself. We've had over 85 successful audits from clients, auditors and regulatory agencies. Most recently, we were audited by the FDA.

"Regarding the FDA audit, no observations were listed on an FDA-483 form, noted Bansi Bhan, CFO / Interim CEO. "The FDA personnel observed and reported that our personnel are proactive in making sure that the proper procedures are in place, noting that '...the firm presented evidence that they were dynamically working toward the building of a robust, quality system.'"

"It may seem unusual, but we welcome audits, a fresh perspective on our system and processes is invaluable" commented Rajiv Modha, Director of QA/QC. "At GBI, both Operations and Quality groups work synergistically, taking a holistic, risk-based approach to quality and compliance, building quality in our processes," continued SooYoung Lee, Senior Vice President, Operations.

"It is refreshing that the people who audit us tend to be very complimentary about the skill level and commitment of our staff, and the sophistication of our facility on an FDA-483 form." noted Bansi.

See what the FDA had to say.

HOME  |  SITEMAP   |   CONTACT US

© Copyright 2011 | Goodwin Biotechnology, Inc.